SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$4.45 USD
-0.04 (-0.89%)
Updated Aug 2, 2024 03:59 PM ET
After-Market: $4.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
SOPHiA GENETICS SA (SOPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.75 | $10.00 | $6.00 | 72.61% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for SOPHiA GENETICS SA comes to $7.75. The forecasts range from a low of $6.00 to a high of $10.00. The average price target represents an increase of 72.61% from the last closing price of $4.49.
Analyst Price Targets (4 )
Broker Rating
SOPHiA GENETICS SA currently has an average brokerage recommendation (ABR) of 1.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.30 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, three are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 60% and 40% of all recommendations. A month ago, Strong Buy made up 60%, while Buy represented 40%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SOPH.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 2 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.30 | 1.30 | 1.30 | 1.38 | 1.38 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
3/6/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1/19/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.30 |
ABR (Last week) | 1.30 |
# of Recs in ABR | 5 |
Average Target Price | $7.75 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 156 of 253 |
Current Quarter EPS Est: | -0.28 |